← back to search

Marcelo Bonomi

Wake Forest University · US
Area of research
Otorhinolaryngology · Oncology
Research interest
Research interests include Medicine, Head and neck squamous-cell carcinoma, Oncology, Cetuximab, Internal medicine, and Nivolumab.
h-index
citations
629
works
11
NIH funding
primary concept
email

Recent publications

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research 2025cited by 16position: middledoi
Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
Cancer Immunology Immunotherapy 2025cited by 8position: middledoi
Predicting cisplatin tolerability in older adults with head and neck cancer – Insights for improved chemoradiation outcomes
Radiotherapy and Oncology 2024cited by 5position: middledoi
A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation
International Journal of Radiation Oncology*Biology*Physics 2023cited by 11position: middledoi
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research 2022cited by 45position: middledoi
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
Journal for ImmunoTherapy of Cancer 2022cited by 36position: middledoi
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
Cancers 2021cited by 57position: middledoi
The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases
Science Advances 2021cited by 42position: middledoi
Sinonasal undifferentiated carcinoma: Institutional trend toward induction chemotherapy followed by definitive chemoradiation
Head & Neck 2020cited by 22position: middledoi
Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients
CHEST Journal 2019cited by 78position: middledoi
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
JAMA Oncology 2018cited by 309position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nabil F. Saba · Emory University5 papers (2018–2025)Christine H. Chung · Diabetes & Endocrine Associates3 papers (2021–2025)José A. Guevara-Patiño · Loyola University Chicago2 papers (2022–2025)James W. Rocco · Massachusetts General Hospital2 papers (2021–2022) · 2 papers (2021–2022)Jameel Muzaffar · University of South Florida2 papers (2021–2022)Michael J. Schell · Moffitt Cancer Center2 papers (2021–2022) · 2 papers (2021–2022)Conor Steuer · Emory Healthcare2 papers (2021–2022)Priyanka Bhateja · The Ohio State University2 papers (2021–2022)Jiannong Li · University of South Florida2 papers (2021–2022)Juan C. Hernandez‐Prera · University of South Florida1 papers (2021–2021)Nicholas M. Durham · AstraZeneca (Japan)1 papers (2022–2022)Bruce M. Wenig · University of South Florida1 papers (2021–2021) · 1 papers (2022–2022)M. Nieves Calvo-Vidal · Cornell University1 papers (2021–2021)Lisle M. Nabell · University of Alabama at Birmingham1 papers (2018–2018)Robbert J.C. Slebos · Vanderbilt University1 papers (2025–2025) · 1 papers (2022–2022)Sophie Wildsmith · AstraZeneca (United Kingdom)1 papers (2018–2018)